Interventional oncology experts

Image-guided, minimally invasive cancer treatment that delivers gene therapies and immunotherapies straight into tumours, sparing surrounding healthy tissue.

1 expert, updated 22 Oct 2026

What our interventional oncology experts do

Interventional oncology at Triple Helix Science starts with imaging: locating the tumour, mapping the tissue around it and deciding whether a needle or catheter route can reach the target without crossing structures that matter. From there the access route is planned, the therapy is prepared, and a precision gene therapy or immunotherapy is delivered into the tumour itself under image guidance rather than circulated through the body. The protocols used are proprietary and IP-protected, and they are run as programmes with governments, sovereign health systems and enterprise pharmaceutical organisations.

How they work

Interventional oncology experts work to a standard set by what the needle misses as much as by what it hits, since the whole argument for image-guided delivery is that healthy tissue either side of the target is spared. The therapeutic payload is not bought in. Triple Helix Science develops its own precision gene therapies and immunotherapies, which means the people planning the delivery route and the people designing what travels down it are working from the same programme. Oncology research sits alongside the firm's work on genomic stability and cellular energy, so an intervention is judged on what it does to the patient's wider physiology, not the lesion alone.

When to bring them in

Interventional oncology experts are worth approaching when a health system or pharmaceutical organisation is deciding how genetic cancer medicines will actually reach patients at national scale, rather than whether they work. The question is usually delivery: a therapy exists or is in development, and the route into the tumour determines its dose, its safety margin and its cost per patient. Triple Helix Science works at the institutional level, with sovereign health systems, research universities, sovereign wealth funds and enterprise pharmaceutical partners, and does not take patients directly.

Newsletters

The most recent piece, published under their own names.

Dr Patrick E. Sewell in The Third StrandThe economics of preventive precision medicine22 Oct 2026

Media reaction

Democratising gene and cell therapy

"Gene and cell therapies are no longer a luxury for the elite. The economies of scale are here, and they're here now. These therapies have real use cases, from the most complex cancers to Alzheimer's and neurodegeneration, and they could transform healthcare systems worldwide. For the first time, preventative healthcare can be democratised on a global scale."
Dr Patrick E. SewellDr Patrick E. Sewell, Founder and Chief Science Officer, Triple Helix Science20 Oct 2026
1 of 2

Questions about interventional oncology experts

The questions we get asked most about interventional oncology, answered plainly.

What is interventional oncology?
Interventional oncology is the image-guided, minimally invasive treatment of cancer, using scans to guide instruments to a tumour and treat it directly instead of through open surgery. In the oncology research programme at Triple Helix Science, that includes targeted delivery of precision gene therapies and immunotherapies into the tumour, so the treatment acts where the disease is rather than across the whole body.
What does working with an interventional oncology expert actually involve?
Interventional oncology specialists at Triple Helix Science work at protocol level: which tumours can be reached under imaging, which gene therapy or immunotherapy is delivered there, and how that protocol is documented and protected as intellectual property. Triple Helix Science was founded by Dr. Patrick Sewell around sovereign partnerships, so engagements sit with governments, sovereign health systems, research universities and enterprise pharmaceutical organisations rather than with individual patients.
How is interventional oncology work judged?
Interventional oncology work is judged first on what happens at the treated site: whether the delivered therapy reaches the tumour, what the tumour does afterwards, and whether the result repeats across patients rather than appearing once. Triple Helix Science applies a second test, which is whether a protocol holds its result when it is handed to a sovereign health system and run at national scale.
Is interventional oncology the same as interventional radiology?
No. Interventional radiology covers image-guided procedures across the whole of medicine, while interventional oncology is the cancer-specific part of that practice, treating the tumour through the same imaging and catheter techniques. The distinction that matters at Triple Helix Science is the payload: interventional oncology is the route by which precision gene therapies and immunotherapies are placed inside a tumour instead of circulated through the body.
When is interventional oncology the right route, and when is it not?
Interventional oncology is worth considering when a tumour can be reached under imaging and the point is to concentrate a gene therapy or immunotherapy at that site rather than across the body. It is not the route for an individual seeking private treatment. Triple Helix Science works with governments, sovereign health systems, research universities, sovereign wealth funds and pharmaceutical organisations, and does not operate direct to consumers.

Contact an expert

Get in touch with an expert on interventional oncology for comment, an interview or a question.

Straight to the Triple Helix Science press team.